DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

The Pharma Data

JULY 11, 2021

TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co-administered medicinal products is expected. Analysis of Safety and Efficacy for up to 2.5 Interactions. Adverse Reactions.

Treatment 52

Treatment Pharmacokinetics Disease Production 52

DrugBank

FEBRUARY 26, 2025

In response, researchers and pharmaceutical companies are exploring novel approaches to antibiotic development. Over the past two decades, many pharmaceutical companies have deprioritized antibiotic research due to high development costs and lower profitability compared to treatments for chronic diseases.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. INSTIs, like cabotegravir, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). TITUSVILLE, N.J. , Use in Specific Populations.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

OCTOBER 14, 2020

AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm. Talking Medicine uses advanced AI to provide pharmaceutical companies with real-time data intelligence. Growth Programme. Dolmatics – U.K.-based

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

Codon

FEBRUARY 23, 2025

In 2024, the pharmaceutical company Gilead announced that a single injection of lenacapavir protected 96 to 100 percent of recipients from HIV for up to six months. Researcher Jerome Horwitz at the Michigan Cancer Foundation developed it as a potential cancer treatment by chemically-modifying thymine, a DNA building block.

Clinical Trials 74

Clinical Trials Virus Vaccine DNA 74